Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer

Perry Grigsby, Adnan Elhammali, Fiona Ruiz, Stephanie Markovina, Michael D. McLellan, Christopher A. Miller, Anupama Chundury, Ngoc Anh L. Ta, Ramachandran Rashmi, John D. Pfeifer, Robert S. Fulton, Todd DeWees, Julie K. Schwarz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the effect of obesity and obesityassociated factors on the outcomes of patients with cervical cancer. Outcomes were evaluated in 591 patients with FIGO Ib to IV cervical cancer treated uniformly with definitive radiation. Patients were stratified into 3 groups based upon pretreatment Body Mass Index (BMI): A ≤ 18.5; B 18.6 - 34.9; and C ≥ 35. The 5-year freedom from failure rates were 58, 59, and 73% for BMI groups A, B, and C (p = 0.01). Overall survival rates were 50, 59, and 68%, respectively (p = 0.02). High expression of phosphorylated AKT (pAKT) was associated with poor outcomes only in non-obese patients. Obese patients with PI3K pathway mutant tumors had a trend toward favorable outcomes, while a similar effect was not observed in non-obese patients. Compared to similar tumors from non-obese hosts, PIK3CA and PTEN mutant tumors from obese patients failed to express high levels of phosphorylated AKT and its downstream targets. These results show that patients with obesity at the time of diagnosis of cervical cancer exhibit improved outcomes after radiation. PI3K/AKT pathway mutations are common in obese patients, but are not associated with activation of AKT signaling.

Original languageEnglish (US)
Pages (from-to)4061-4073
Number of pages13
JournalOncotarget
Volume9
Issue number3
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinases
Uterine Cervical Neoplasms
Mutation
Body Mass Index
Obesity
Radiation
Neoplasms
Survival Rate

Keywords

  • Cervical cancer
  • Mutation
  • Obesity
  • PI3K
  • PTEN

ASJC Scopus subject areas

  • Oncology

Cite this

Grigsby, P., Elhammali, A., Ruiz, F., Markovina, S., McLellan, M. D., Miller, C. A., ... Schwarz, J. K. (2018). Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer. Oncotarget, 9(3), 4061-4073. https://doi.org/10.18632/oncotarget.23664

Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer. / Grigsby, Perry; Elhammali, Adnan; Ruiz, Fiona; Markovina, Stephanie; McLellan, Michael D.; Miller, Christopher A.; Chundury, Anupama; Ta, Ngoc Anh L.; Rashmi, Ramachandran; Pfeifer, John D.; Fulton, Robert S.; DeWees, Todd; Schwarz, Julie K.

In: Oncotarget, Vol. 9, No. 3, 01.01.2018, p. 4061-4073.

Research output: Contribution to journalArticle

Grigsby, P, Elhammali, A, Ruiz, F, Markovina, S, McLellan, MD, Miller, CA, Chundury, A, Ta, NAL, Rashmi, R, Pfeifer, JD, Fulton, RS, DeWees, T & Schwarz, JK 2018, 'Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer', Oncotarget, vol. 9, no. 3, pp. 4061-4073. https://doi.org/10.18632/oncotarget.23664
Grigsby, Perry ; Elhammali, Adnan ; Ruiz, Fiona ; Markovina, Stephanie ; McLellan, Michael D. ; Miller, Christopher A. ; Chundury, Anupama ; Ta, Ngoc Anh L. ; Rashmi, Ramachandran ; Pfeifer, John D. ; Fulton, Robert S. ; DeWees, Todd ; Schwarz, Julie K. / Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer. In: Oncotarget. 2018 ; Vol. 9, No. 3. pp. 4061-4073.
@article{6f06fc0469e74805974a828ebf8c5019,
title = "Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer",
abstract = "The purpose of this study was to evaluate the effect of obesity and obesityassociated factors on the outcomes of patients with cervical cancer. Outcomes were evaluated in 591 patients with FIGO Ib to IV cervical cancer treated uniformly with definitive radiation. Patients were stratified into 3 groups based upon pretreatment Body Mass Index (BMI): A ≤ 18.5; B 18.6 - 34.9; and C ≥ 35. The 5-year freedom from failure rates were 58, 59, and 73{\%} for BMI groups A, B, and C (p = 0.01). Overall survival rates were 50, 59, and 68{\%}, respectively (p = 0.02). High expression of phosphorylated AKT (pAKT) was associated with poor outcomes only in non-obese patients. Obese patients with PI3K pathway mutant tumors had a trend toward favorable outcomes, while a similar effect was not observed in non-obese patients. Compared to similar tumors from non-obese hosts, PIK3CA and PTEN mutant tumors from obese patients failed to express high levels of phosphorylated AKT and its downstream targets. These results show that patients with obesity at the time of diagnosis of cervical cancer exhibit improved outcomes after radiation. PI3K/AKT pathway mutations are common in obese patients, but are not associated with activation of AKT signaling.",
keywords = "Cervical cancer, Mutation, Obesity, PI3K, PTEN",
author = "Perry Grigsby and Adnan Elhammali and Fiona Ruiz and Stephanie Markovina and McLellan, {Michael D.} and Miller, {Christopher A.} and Anupama Chundury and Ta, {Ngoc Anh L.} and Ramachandran Rashmi and Pfeifer, {John D.} and Fulton, {Robert S.} and Todd DeWees and Schwarz, {Julie K.}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23664",
language = "English (US)",
volume = "9",
pages = "4061--4073",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer

AU - Grigsby, Perry

AU - Elhammali, Adnan

AU - Ruiz, Fiona

AU - Markovina, Stephanie

AU - McLellan, Michael D.

AU - Miller, Christopher A.

AU - Chundury, Anupama

AU - Ta, Ngoc Anh L.

AU - Rashmi, Ramachandran

AU - Pfeifer, John D.

AU - Fulton, Robert S.

AU - DeWees, Todd

AU - Schwarz, Julie K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The purpose of this study was to evaluate the effect of obesity and obesityassociated factors on the outcomes of patients with cervical cancer. Outcomes were evaluated in 591 patients with FIGO Ib to IV cervical cancer treated uniformly with definitive radiation. Patients were stratified into 3 groups based upon pretreatment Body Mass Index (BMI): A ≤ 18.5; B 18.6 - 34.9; and C ≥ 35. The 5-year freedom from failure rates were 58, 59, and 73% for BMI groups A, B, and C (p = 0.01). Overall survival rates were 50, 59, and 68%, respectively (p = 0.02). High expression of phosphorylated AKT (pAKT) was associated with poor outcomes only in non-obese patients. Obese patients with PI3K pathway mutant tumors had a trend toward favorable outcomes, while a similar effect was not observed in non-obese patients. Compared to similar tumors from non-obese hosts, PIK3CA and PTEN mutant tumors from obese patients failed to express high levels of phosphorylated AKT and its downstream targets. These results show that patients with obesity at the time of diagnosis of cervical cancer exhibit improved outcomes after radiation. PI3K/AKT pathway mutations are common in obese patients, but are not associated with activation of AKT signaling.

AB - The purpose of this study was to evaluate the effect of obesity and obesityassociated factors on the outcomes of patients with cervical cancer. Outcomes were evaluated in 591 patients with FIGO Ib to IV cervical cancer treated uniformly with definitive radiation. Patients were stratified into 3 groups based upon pretreatment Body Mass Index (BMI): A ≤ 18.5; B 18.6 - 34.9; and C ≥ 35. The 5-year freedom from failure rates were 58, 59, and 73% for BMI groups A, B, and C (p = 0.01). Overall survival rates were 50, 59, and 68%, respectively (p = 0.02). High expression of phosphorylated AKT (pAKT) was associated with poor outcomes only in non-obese patients. Obese patients with PI3K pathway mutant tumors had a trend toward favorable outcomes, while a similar effect was not observed in non-obese patients. Compared to similar tumors from non-obese hosts, PIK3CA and PTEN mutant tumors from obese patients failed to express high levels of phosphorylated AKT and its downstream targets. These results show that patients with obesity at the time of diagnosis of cervical cancer exhibit improved outcomes after radiation. PI3K/AKT pathway mutations are common in obese patients, but are not associated with activation of AKT signaling.

KW - Cervical cancer

KW - Mutation

KW - Obesity

KW - PI3K

KW - PTEN

UR - http://www.scopus.com/inward/record.url?scp=85040165139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040165139&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23664

DO - 10.18632/oncotarget.23664

M3 - Article

AN - SCOPUS:85040165139

VL - 9

SP - 4061

EP - 4073

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -